European Journal of Health Economics

Papers
(The TQCC of European Journal of Health Economics is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19693
Which multi-attribute utility instruments are recommended for use in cost-utility analysis? A review of national health technology assessment (HTA) guidelines144
Historical evidence for economic effects of COVID-19134
Do renewable energy and health expenditures improve load capacity factor in the USA and Japan? A new approach to environmental issues85
COVID-19 and income inequality in OECD countries84
Cost and effects of integrated care: a systematic literature review and meta-analysis76
Are regions equal in adversity? A spatial analysis of spread and dynamics of COVID-19 in Europe49
Comparison of ARIMA, ETS, NNAR, TBATS and hybrid models to forecast the second wave of COVID-19 hospitalizations in Italy41
The COVID-19 crisis and telework: a research survey on experiences, expectations and hopes39
An exploration of methods for obtaining 0 = dead anchors for latent scale EQ-5D-Y values36
HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies36
Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life34
The economic burden of obesity in Italy: a cost-of-illness study33
More room for telemedicine after COVID-19: lessons for primary care?32
Determinants of willingness to pay for health services: a systematic review of contingent valuation studies31
COVID-19 and the role of inequality in French regional departments30
Healthcare expenditure and carbon footprint in the USA: evidence from hidden cointegration approach27
How expensive are post-traumatic stress disorders? Estimating incremental health care and economic costs on anonymised claims data26
EQ-5D-5L Bulgarian population norms25
Health effects from heat waves in France: an economic evaluation24
The “red herring” after 20 years: ageing and health care expenditures23
Efficiency and productivity of health systems in prevention and control of non-communicable diseases in China, 2008–201522
Modelling Covid-19 under uncertainty: what can we expect?22
Self vs. other, child vs. adult. An experimental comparison of valuation perspectives for valuation of EQ-5D-Y-3L health states22
The remarkably frequent use of EQ-5D in non-economic research22
Impacts of air pollution on health: evidence from longitudinal cohort data of patients with cardiovascular diseases21
Is stronger religious faith associated with a greater willingness to take the COVID-19 vaccine? Evidence from Israel and Japan21
Discrete choice experiments to generate utility values for multi-attribute utility instruments: a systematic review of methods20
The effect of long-term care public benefits and insurance on informal care from outside the household: empirical evidence from Italy and Spain19
Measuring health-related quality of life and well-being: a head-to-head psychometric comparison of the EQ-5D-5L, ReQoL-UI and ICECAP-A19
The impact of the great economic crisis on mental health care in Italy19
Willingness to pay for an early warning system for infectious diseases19
Effect of financial inclusion on out-of-pocket health expenditure: empirics from Ghana18
Cost effectiveness of breast cancer screening and prevention: a systematic review with a focus on risk-adapted strategies18
General population normative data for the EQ-5D-3L in the five largest European economies18
Does the universal medical insurance system reduce catastrophic health expenditure among middle-aged and elderly households in China? A longitudinal analysis18
Evaluating the psychometric properties of the EQ-5D-5L and SF-6D among patients with haemophilia17
Economics of mental well-being: a prospective study estimating associated health care costs and sickness benefit transfers in Denmark17
The excess economic burden of mental disorders: findings from a cross-sectional prevalence survey in Austria17
Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (NASH) in the United Kingdom (UK) in 201816
Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression16
The relationship between renewable energy use and health expenditures in EU countries16
Predictors of negotiated prices for new drugs in Germany15
What is the best approach to adopt for identifying the domains for a new measure of health, social care and carer-related quality of life to measure quality-adjusted life years? Application to the dev15
Evaluation of the cost-utility of phosphate binders as a treatment option for hyperphosphatemia in chronic kidney disease patients: a systematic review and meta-analysis of the economic evaluations15
Can the Covid19 pandemic affect the achievement of the ‘Zero Hunger’ goal? Some preliminary reflections15
Patient-caregiver agreement and test–retest reliability of the EQ-5D-Y-3L and EQ-5D-Y-5L in paediatric patients with haematological malignancies15
Health state utility values by cancer stage: a systematic literature review14
The impact of COVID-19 pandemic on insurance demand: the case of China14
The Italian NHS at regional level: same in theory, different in practice14
Economic analysis of open versus laparoscopic versus robotic hepatectomy: a systematic review and meta-analysis14
Health-related quality of life in elderly people with hypertension and the estimation of minimally important difference using EQ-5D-5L in Hong Kong SAR, China14
Incidence and costs of hospitalized adult influenza patients in The Netherlands: a retrospective observational study14
A guide to extending and implementing generalized risk-adjusted cost-effectiveness (GRACE)14
Cost-effectiveness of a non-pharmacological treatment vs. “care as usual” in day care centers for community-dwelling older people with cognitive impairment: results from the German randomized controll14
A cost-effectiveness analysis of pembrolizumab with or without chemotherapy for the treatment of patients with metastatic, non-squamous non-small cell lung cancer and high PD-L1 expression in Switzerl14
Testing measurement properties of two EQ-5D youth versions and KIDSCREEN-10 in China13
Cost-effectiveness and budget impact of venetoclax in combination with rituximab in relapsed/refractory chronic lymphocytic leukemia in Switzerland13
Very high and low residual spenders in private health insurance markets: Germany, The Netherlands and the U.S. Marketplaces13
Comparison of the three-level and the five-level versions of the EQ-5D13
Transforming discrete choice experiment latent scale values for EQ-5D-3L using the visual analogue scale12
Do European pharmacists really have to trespass on medicine?12
Machine learning versus regression modelling in predicting individual healthcare costs from a representative sample of the nationwide claims database in France12
The impact of social health insurance on rural populations12
Income level and antibiotic misuse: a systematic review and dose–response meta-analysis11
Value-based pricing for advanced therapy medicinal products: emerging affordability solutions11
Income and conversion handicaps: estimating the impact of child chronic illness/disability on family income and the extra cost of child chronic illness/child disability in Ireland using a standard of 11
COVID-19 health policy evaluation: integrating health and economic perspectives with a data envelopment analysis approach11
Reassessing the impact of health expenditure on income growth in the face of the global sanitary crisis: the case of developing countries11
The pass-through of alcohol excise taxes to prices in OECD countries11
Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges11
Does socioeconomic status affect hospital utilization and health outcomes of chronic disease patients?11
Work ethics, stay-at-home measures and COVID-19 diffusion11
The cost of lost productivity due to premature mortality associated with COVID-19: a Pan-European study11
Should health technology assessment be more patient centric? If so, how?11
The economic burden of amyotrophic lateral sclerosis: a systematic review11
Preferences for COVID-19 epidemic control measures among French adults: a discrete choice experiment10
Patterns of care and cost profiles of women with breast cancer in Italy: EPICOST study based on real world data10
‘Relative Consent’ or ‘Presumed Consent’? Organ donation attitudes and behaviour10
Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting10
Has the development of cancer biomarkers to guide treatment improved health outcomes?10
Value drivers of development stage biopharma companies10
The causal impact of sugar taxes on soft drink sales: evidence from France and Hungary10
Cost-effectiveness of biennial screening for diabetes related retinopathy in people with type 1 and type 2 diabetes compared to annual screening10
Cost-effectiveness of the latent tuberculosis screening program for migrants in Stockholm Region10
The effect of alcohol tax changes on retail prices: how do on-trade alcohol retailers pass through tax changes to consumers?10
The effect of mental and physical health problems on sickness absence10
EQ-5D-5L Portuguese population norms9
Health-related quality of life and health utilities in insulin-treated type 2 diabetes: the impact of related comorbidities/complications9
Mapping of the EORTC QLQ-C30 to EQ-5D-5L index in patients with lymphomas9
Reliability and validity of using EQ-5D-5L among healthy and adolescents with major mental health disorders in Ethiopia9
The residential healthcare for the elderly in Italy: some considerations for post-COVID-19 policies9
Estimating the monetary value of health and capability well-being applying the well-being valuation approach9
Quantifying the economic impact of caregiving for Duchenne muscular dystrophy (DMD) in Spain9
A European multinational cost-effectiveness analysis of empagliflozin in heart failure with reduced ejection fraction9
The impact of the diabetes management incentive on diabetes-related services: evidence from Ontario, Canada9
Cost-minimization analysis of immunoglobulin treatment of primary immunodeficiency diseases in Spain9
The common interests of health protection and the economy: evidence from scenario calculations of COVID-19 containment policies9
Cost–utility analysis of risk-reducing strategies to prevent breast and ovarian cancer in BRCA-mutation carriers in Switzerland9
Voluntary private health insurance, health-related behaviours and health outcomes: evidence from Russia9
The impact of decentralisation on the performance of health care systems: a non-linear relationship9
Were we happy and we didn’t know it? A subjective dynamic and financial assessment pre-, during and post-COVID-198
Willingness-to-pay for cancer treatment and outcome: a systematic review8
The impact of nurse staffing levels on nursing-sensitive patient outcomes: a multilevel regression approach8
Economic evidence with respect to cost-effectiveness of the transitional care model among geriatric patients discharged from hospital to home: a systematic review8
Costs and where to find them: identifying unit costs for health economic evaluations of diabetes in France, Germany and Italy8
Cost-effectiveness of screening smokers and ex-smokers for lung cancer in the Netherlands in different age groups8
Real-world study of direct medical and indirect costs and time spent in healthcare in patients with chronic graft versus host disease8
Mapping MacNew Heart Disease Quality of Life Questionnaire onto country-specific EQ-5D-5L utility scores: a comparison of traditional regression models with a machine learning technique8
Economic and social cost of epilepsy in Poland: 5-year analysis8
Long-term cost of breast cancer treatment to the United States Medicare Program by stage at diagnosis8
Cost-effectiveness of metabolic surgery for the treatment of type 2 diabetes and obesity: a systematic review of economic evaluations8
The economics of alternative payment models for pharmaceuticals8
Business cycle and mortality in Spain8
Comparing EQ-5D-3L and EQ-5D-5L in measuring the HRQoL burden of 4 health conditions in China8
Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations8
Evaluating the conduct and application of health utility studies: a review of critical appraisal tools and reporting checklists7
The association between bed occupancy rates and hospital quality in the English National Health Service7
Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations7
The effects of patient cost-sharing on health expenditure and health among older people: Heterogeneity across income groups7
Timing of non-pharmaceutical interventions to mitigate COVID-19 transmission and their effects on mobility: a cross-country analysis7
Can drones save lives and money? An economic evaluation of airborne delivery of automated external defibrillators7
Costs and management of patients with hemophilia A in France: the Hemraude study7
Assessing the cost-effectiveness of COVID-19 vaccines in a low incidence and low mortality setting: the case of Thailand at start of the pandemic7
General practitioners’ income and activity: the impact of multi-professional group practice in France7
Consideration of quality of life in the health technology assessments of rare disease treatments7
0.023074865341187